Metrics to compare | 300642 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship300642PeersSector | |
|---|---|---|---|---|
P/E Ratio | 135.8x | 31.7x | −0.2x | |
PEG Ratio | 7.35 | −1.14 | 0.00 | |
Price/Book | 1.8x | 2.5x | 2.6x | |
Price / LTM Sales | 6.5x | 5.1x | 2.8x | |
Upside (Analyst Target) | - | 19.2% | 60.9% | |
Fair Value Upside | Unlock | 9.2% | 9.5% | Unlock |
Tellgen Corporation research, development, production, and sales of in-vitro diagnostic products in China and internationally. The company offers fully automatic flow fluorescence analyzer and CLIA analyzer; molecular test such as HPV test, lung cancer, colon cancer, personalized medicine, and infertility; and automatic integrated gene detection systems. It also provides tumor detection products; HPV nucleic acid testing products; methylation mutation detection products; detection products for invasive fungal diseases. The company was founded in 2003 and is based in Shanghai, China.